Vision Training for Age-Related Macular Degeneration
(FLAP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores new methods to assist individuals with age-related macular degeneration, a condition that causes vision loss. It examines whether eye training can improve vision by testing two methods: one focuses on visual sensitivity (Training visual sensitivity), and the other combines various visual tasks (Combination training). Individuals diagnosed with macular degeneration, who have severely impaired vision in both eyes and have experienced these issues for at least two years, might be suitable candidates. The research aims to discover treatments that could benefit millions facing vision loss. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that may lead to new treatments for vision loss.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this vision training is safe for individuals with age-related macular degeneration?
Research has shown that training the eyes to see better can aid individuals with age-related macular degeneration (AMD). Some studies have found that vision can improve through exercises that enhance the ability to notice details more clearly. This training is generally safe, as it relies on exercises rather than drugs or surgery.
For training that combines various exercises, specific safety information remains less clear. However, since it involves exercises and not medication, it is likely low-risk. These methods are non-invasive, meaning they don't involve surgery or drugs, which typically results in fewer side effects.12345Why are researchers excited about this trial?
Researchers are excited about the Vision Training for Age-Related Macular Degeneration because it offers a unique approach compared to traditional treatments like anti-VEGF injections. Unlike these standard therapies that mainly focus on slowing disease progression by targeting blood vessel growth, this trial explores perceptual learning techniques to enhance visual processing. The "Training visual sensitivity" arm specifically aims to improve how the brain processes visual information, potentially enhancing visual acuity through exercises with Gabor patches. Meanwhile, the "Combination training" arm combines visual sensitivity training with spatial integration tasks, potentially offering synergistic benefits that surpass the effects of either method alone. This innovative focus on retraining the brain's visual processing is what makes these treatments stand out.
What evidence suggests that this trial's treatments could be effective for age-related macular degeneration?
Research has shown that training to enhance visual acuity can benefit individuals with age-related macular degeneration (AMD). Studies have found that this training can clarify and sharpen vision, assisting with everyday tasks and making daily activities easier for those with low vision. In this trial, participants will join different treatment arms. One arm will focus on training visual sensitivity, which has shown promise in improving acuity. Another arm will explore combination training, where researchers are investigating whether combining different training methods proves more effective than using just one. Although the effectiveness of this combination is still under study, early results suggest it might improve overall vision.678910
Are You a Good Fit for This Trial?
This trial is for adults aged 18-89 with severe vision impairment (20/100 or worse) due to Macular Degeneration, confirmed by an ophthalmologist. Participants must have had this condition for at least two years and live within 50 miles of the study site. Those with certain body measurements, metal implants, claustrophobia, hearing impairments, significant head injuries, mental health conditions like hallucinations/delusions, or specific tattoos near the head cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Training
Participants undergo perceptual learning training focusing on visual sensitivity, spatial integration, and attention and eye-movements.
Follow-up
Participants are monitored for changes in visual processing and brain plasticity after training completion.
What Are the Treatments Tested in This Trial?
Interventions
- Combination training
- Training visual sensitivity
Trial Overview
The study explores how different training methods can improve visual sensitivity in people suffering from low vision caused by Macular Degeneration. It aims to understand how the brain adapts and learns despite central vision loss which could lead to new treatments that help preserve sight.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
A standard Perceptual Learning approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold- level contrast. Preliminary data, using this method, in normally seeing and MD participants show both feasibility and preliminary evidence that this training gives rise to improvements in acuity.
In combination training, investigators test the extent to which a combined training gives rise to the joint benefits of each training individually, or integrative benefits potentially surpassing benefits of the individual training alone. The visual sensitivity task will alternate across blocks with the spatial integration task, using the timing of targets and location switches from spatial attention training.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
University of California, Riverside
Collaborator
Published Research Related to This Trial
Citations
Improving Outcomes for Patients with Age-Related Macular ...
Currently there is no effective treatment for the majority of patients suffering from dry AMD. Cataract and AMD often coexist in patients. In ...
Eccentric Viewing Training for Age-Related Macular Disease
On average, visual acuity deteriorated by 0.20 logMAR (SD: 0.47) over the study, from a mean value of 0.67 logMAR (SD: 0.24) to 0.87 logMAR (SD: 0.41). There ...
Re: Rubin et al: Eccentric Viewing Training for Age-related ...
Rubin et al.: Eccentric Viewing Training for Age-Related Macular Disease: Results of a Randomized Controlled Trial (the EFFECT Study)
Predicting risk of late age-related macular degeneration ...
Here, we demonstrate how deep learning and survival analysis can predict the probability of progression to late AMD using 3298 participants ( ...
Effectiveness of eccentric viewing training for daily visual ...
Meta-analysis was conducted to examine effectiveness of eccentric viewing training on daily visual activities for individuals with age-related ...
Combination Therapy for Age-Related Macular ...
This randomized, controlled trial addresses the potential supplemental therapeutic effect of intravitreal injection of Triamcinolone Acetonide ...
Rethinking Clinical Trials in Age-Related Macular Degeneration
This review highlights the transformative potential of AI in optimizing clinical trial outcomes for patients with nAMD or GA secondary to AMD.
Combined automated screening for age-related macular ...
The AMD and DR screening tools achieved excellent performance operating together to identify two retinal diseases prospectively in mixed datasets, demonstrating ...
Age-related macular degeneration: Epidemiology, genetics ...
Age-related macular degeneration (AMD) is a complex eye disorder and is the leading cause of incurable blindness worldwide in the elderly.
A Study to Evaluate the Safety and Efficacy of RQC for AMD
To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.